Medexus Pharmaceuticals Inc (MDP : TSX)
Common Stock
$4.05
CAD
-0.02 (-0.49%)
Last updated: 2026-06-23
MDP
Medexus Pharmaceuticals Inc
WealthAwesomePerformance
1 Day
-0.49%
1 Week
+1.50%
1 Month
+1.50%
YTD
+31.07%
Key Statistics
Market Cap
$131.79M
52W High
$4.25
52W Low
$2.47
P/E Ratio
-
50 Day MA
$3.98
200 Day MA
$3.17
Beta
1.84
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 6/23/2026 | $4.04 | $4.10 | $3.93 | $4.05 | $4.05 | 29,262 |
| 6/22/2026 | $4.06 | $4.21 | $4.03 | $4.07 | $4.07 | 28,594 |
| 6/19/2026 | $4.14 | $4.25 | $4.09 | $4.20 | $4.20 | 24,315 |
| 6/18/2026 | $4.07 | $4.12 | $3.99 | $4.11 | $4.11 | 35,948 |
| 6/17/2026 | $4.04 | $4.13 | $3.99 | $4.02 | $4.02 | 21,207 |
| 6/16/2026 | $4.18 | $4.22 | $3.97 | $3.99 | $3.99 | 39,174 |
| 6/15/2026 | $4.00 | $4.19 | $4.00 | $4.18 | $4.18 | 24,151 |
| 6/12/2026 | $4.07 | $4.07 | $3.95 | $4.01 | $4.01 | 13,573 |
| 6/11/2026 | $3.89 | $4.12 | $3.89 | $4.05 | $4.05 | 51,440 |
| 6/10/2026 | $4.03 | $4.16 | $4.00 | $4.00 | $4.00 | 46,134 |
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 65.7% over the next 12 months.
Consensus
No RatingAvg. Target
C$6.71
+65.7% Upside
Current Price
C$4.05
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
33.1%
Annualized
90-Day Vol
40.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$4.84
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$4.30 | C$3.83 โ C$4.82 |
| 60 trading days | C$4.56 | C$3.88 โ C$5.36 |
| 90 trading days | C$4.84 | C$3.97 โ C$5.90 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Medexus Pharmaceuticals Inc
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on various therapeutic areas comprising allergy, dermatology, hematology, oncology, rheumatology, and rare diseases. Its primary products include IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; GRAFAPEX, an injection to treat allogeneic hematopoietic stem cell transplantation in adult and pediatric patients, acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS); and Gleolan, an optical imaging agent for patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. was founded in 2000 and is based in Toronto, Canada.
Financials
- Revenue (TTM)
- $99.43M
- EBITDA
- $13.44M
- Profit Margin
- -0.27%
- ROE (TTM)
- -0.64%
- EPS (Diluted)
- -0.03
- Book Value
- 2.29
Classification
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
Advertisement
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About MDP
Articles Featuring MDP.TO
Latest articles and analysis covering MDP.TO
Why Medexus Pharmaceuticals Inc stock is rising today
Medexus Pharmaceuticals Inc (MDP.TO) saw a 2.96% increase in its stock price today, driven by positive developments in its product line and strategic initiatives aimed at enhancing shareholder value.
Why Medexus Pharmaceuticals Inc stock is gaining today
Medexus Pharmaceuticals Inc (MDP.TO) saw a 1.70% increase in stock price, closing at CA$4.18. This rise is attributed to positive investor sentiment surrounding the company's strategic initiatives and product performance.
Why Medexus Pharmaceuticals Inc stock is gaining today
Medexus Pharmaceuticals Inc (MDP.TO) has gained 1.49% in the latest trading session, closing at CA$4.08. The uptick reflects growing investor confidence in the company's strategic initiatives and product performance.
Why Medexus Pharmaceuticals Inc stock is gaining today
Medexus Pharmaceuticals Inc (MDP.TO) has gained 0.75% in the last trading session, closing at CA$4.02. This uptick may reflect investor confidence in the company's future prospects, particularly regarding its product GRAFAPEX.
Why Medexus Pharmaceuticals Inc stock is sliding today
Medexus Pharmaceuticals Inc's stock slid 4.55% today, closing at CA$3.99. This decline raises concerns among investors, particularly given the absence of significant news to explain the downturn.
Why Medexus Pharmaceuticals Inc stock is tanking today
Medexus Pharmaceuticals Inc stock fell by 1.73% today, closing at CA$3.98 amid investor concerns over a recent public offering. The company's strategic decisions will be crucial as it seeks to regain market confidence.
